ReviewThe Urologic clinics of North America2010
Blood and tissue biomarkers in prostate cancer: state of the art.
Review in The Urologic clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 40 citations in OpenAlex.
- Proteomic Profiling of Serum-Derived Exosomes from Ethnically Diverse Prostate Cancer Patients.Cancer investigation · 2016Article
- Article
- Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer.PloS one · 2014Article
- Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.Genome medicine · 2013Article
- The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer.International urology and nephrology · 2012Article
- Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.The Lancet. Oncology · 2012Article
- Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy.Prostate cancer and prostatic diseases · 2012Article
- Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012Article
- Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.The Prostate · 2012Article
- Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.PloS one · 2012Article
- A new dimension of FDG-PET interpretation: assessment of tumor biology.European journal of nuclear medicine and molecular imaging · 2011Review
- A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer.PloS one · 2011Article
- Being more realistic about the public health impact of genomic medicine.PLoS medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The prevalence of prostate cancer (PCa) is high and increases with age. PCa is the most common cutaneous cancer in American men. Prostate-specific antigen (PSA) screening has impacted the detection of PCa and is directly responsible for a dramatic decrease in stage at diagnosis. Gleason score and stage at the time of diagnosis remain the mainstay to predict prognosis, in the absence of more accurate and reliable tissue or blood biomarkers. Despite extensive research efforts, very few biomarkers of PCa have been introduced to date in clinical practice. Even screening with PSA has recently been questioned. A thorough analysis of all tissue and serum biomarkers in prostate cancer research cannot be easily synthesized, and goes beyond the scope of the present article. Therefore the authors focus here on the most recently reported tissue and circulating biomarkers for PCa whose application in clinical practice is either current or expected in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.